Calidi Biotherapeutics
Develops systemic oncolytic-virus platforms that deliver therapeutic payloads into tumors.
Something off on this page? Send us feedback.
Profile
Develops investigational oncolytic-virus platforms for cancer, led by RedTail, which is designed to circulate to metastatic sites, replicate selectively in tumor cells, and produce therapeutic payloads locally.
Develops RedTail, an extracellular-enveloped vaccinia-virus platform designed for systemic delivery to metastatic solid tumors. Its lead candidate is intended to replicate selectively in tumor cells and express an immune-stimulating payload in the tumor microenvironment; other RedTail programs explore in-situ T-cell engagers. NeuroNova and SuperNova are legacy platforms that use stem-cell carriers for high-grade glioma and intratumoral solid tumors.
Operates from San Diego, with research, process-development, and assay work supplemented by academic partners, CROs, and CDMOs in the United States, Germany, and Australia. Every candidate remains investigational, and evidence for RedTail’s systemic delivery and payload expression remains preclinical. Owns no commercial manufacturing facility and has no long-term supply arrangements with outside manufacturers.
Company facts
Key statistics
Year to date −93.1% · Average volume (30d) 437.4K
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | — | −$2.94 | — | — | — | — | +3.25% |
| Mar 30, 2026Q4 FY25 | — | −$0.43 | — | — | — | — | −0.26% |
| Mar 27, 2026Q4 FY25 | −$1.56 | −$0.57 | +63.5% | — | — | — | −11.55% |
| Nov 11, 2025Q3 FY25 | −$1.68 | −$2.21 | −31.5% | — | — | — | +4.14% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$426.0K | $0 | |
| Operating income | −$5.1M | −$5.7M | −$5.0M | −$4.5M | −$4.2M | −$4.2M | |
| Net income | −$5.0M | −$5.7M | −$5.1M | −$4.1M | −$4.1M | −$4.2M | |
| Diluted EPS | −$35.36 | −$31.84 | −$35.36 | −$8.96 | −$6.88 | −$2.94 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $4.1M · Total debt $1.3M · Total assets $7.2M · Shareholders' equity $3.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 460.4K · Float 343.8K · 74.7% free float
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Genelux
Systemic vaccinia rival in metastatic lung and other solid tumors.
- Oncolytics Biotech
Intravenous oncolytic-virus rival across metastatic solid tumors.
- Replimune Group
Armed HSV rival in oncolytic-immunotherapy combinations.
- Candel Therapeutics
Locally delivered viral-gene-therapy rival in solid tumors.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Calidi Biotherapeutics | $1.32 | +0.76% | $607.8K | — | — | — | — |
| Genelux | $2.66 | −0.31% | $119.3M | — | — | 14,909.4 | −98.2% |
| Oncolytics Biotech | $0.8526 | −0.79% | $86.0M | — | — | — | — |
| Replimune Group | $15.45 | −0.39% | $1.30B | — | — | — | — |
| Candel Therapeutics | $13.07 | +0.08% | $957.6M | — | — | — | — |
| Median | — | — | 14,909.4 | −98.2% |